Your browser is no longer supported. Please, upgrade your browser.
ACRS Aclaris Therapeutics, Inc. daily Stock Chart
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.75 Insider Own3.40% Shs Outstand43.01M Perf Week25.56%
Market Cap48.60M Forward P/E- EPS next Y-1.20 Insider Trans0.00% Shs Float37.33M Perf Month-0.88%
Income-113.50M PEG- EPS next Q-0.33 Inst Own80.60% Short Float13.87% Perf Quarter-39.25%
Sales4.20M P/S11.57 EPS this Y-10.10% Inst Trans5.76% Short Ratio7.19 Perf Half Y-3.83%
Book/sh1.69 P/B0.67 EPS next Y13.70% ROA-88.50% Target Price4.50 Perf Year-81.57%
Cash/sh1.74 P/C0.65 EPS next 5Y- ROE-136.00% 52W Range0.70 - 7.15 Perf YTD-40.21%
Dividend- P/FCF- EPS past 5Y-57.10% ROI-158.70% 52W High-84.20% Beta0.58
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin4.10% 52W Low61.43% ATR0.13
Employees77 Current Ratio3.70 Sales Q/Q-38.90% Oper. Margin- RSI (14)52.67 Volatility9.59% 13.55%
OptionableYes Debt/Eq0.00 EPS Q/Q22.60% Profit Margin- Rel Volume0.16 Prev Close1.17
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume720.00K Price1.13
Recom1.60 SMA2010.05% SMA50-11.41% SMA200-32.39% Volume114,221 Change-3.42%
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Mar-17-20 02:46AM  Edited Transcript of ACRS earnings conference call or presentation 25-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-25-20 04:01PM  Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights GlobeNewswire
Feb-24-20 07:31AM  Is Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Paid At A Competitive Rate? Simply Wall St.
Feb-19-20 05:00PM  Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020 GlobeNewswire
Feb-10-20 07:00AM  Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire
Jan-13-20 05:03PM  Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I Zacks
Jan-10-20 07:13AM  The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga +17.20%
05:40AM  Some Aclaris Therapeutics (NASDAQ:ACRS) Shareholders Have Taken A Painful 94% Share Price Drop Simply Wall St.
Jan-09-20 04:27PM  Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor GlobeNewswire
Jan-08-20 08:00AM  Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors GlobeNewswire
Dec-24-19 12:00PM  Aclaris (ACRS) Upgraded to Buy: Here's Why Zacks
Dec-12-19 10:33AM  Did Hedge Funds Drop The Ball On Aclaris Therapeutics, Inc. (ACRS) ? Insider Monkey
Nov-27-19 03:23PM  Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS) Business Wire
Nov-21-19 11:39AM  Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS) Business Wire -11.24%
Nov-18-19 05:34PM  Rigel Gets Positive CHMP Review for Thrombocytopenia Drug Zacks
Nov-17-19 07:14AM  Edited Transcript of ACRS earnings conference call or presentation 7-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-12-19 04:01PM  Aclaris Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-19 04:01PM  Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs GlobeNewswire
Oct-31-19 04:01PM  Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 GlobeNewswire
Oct-29-19 10:33AM  Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +14.46%
Oct-25-19 07:12AM  The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug Benzinga +5.95%
Oct-24-19 04:01PM  Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1) GlobeNewswire
Oct-17-19 09:46AM  Company News for Oct 17, 2019 Zacks +6.41%
Oct-14-19 10:28AM  Aclaris Divests Rhofade to EPI Health for $55M, Shares Up Zacks
Oct-11-19 11:46AM  Wayne biopharma sells rosacea therapy in deal that could bring in $55M American City Business Journals +19.33%
Oct-10-19 04:02PM  Aclaris Therapeutics Announces Divestiture of RHOFADE® GlobeNewswire
Oct-09-19 07:58AM  The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug Benzinga
Oct-08-19 05:01PM  Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1% GlobeNewswire
01:42PM  Edited Transcript of ACRS earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Oct-07-19 07:25AM  Does Market Volatility Impact Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Share Price? Simply Wall St.
Oct-06-19 10:00AM  Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm GlobeNewswire
Oct-03-19 07:28AM  Top Ranked Momentum Stocks to Buy for October 3rd Zacks
Sep-30-19 12:15PM  FINAL DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -9.24%
10:44AM  FINAL SEPT. 30 DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important Deadline in Securities Class Action ACRS GlobeNewswire
Sep-28-19 06:30PM  DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:00AM  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm Business Wire
Sep-27-19 08:15PM  FINAL DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:00PM  Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
12:21PM  Top Ranked Momentum Stocks to Buy for September 27th Zacks
11:00AM  DEADLINE ALERT for ACRS, GTT, JE, and NKTR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:36AM  Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-26-19 04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS PR Newswire -11.65%
04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS CNW Group
11:17AM  Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS GlobeNewswire
08:19AM  Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue? Zacks
Sep-25-19 08:48PM  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm PR Newswire +6.83%
03:38PM  ACLARIS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm Newsfile
03:15PM  5-Day Deadline Alert: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:00AM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. GlobeNewswire
10:35AM  Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:00AM  Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade Zacks
Sep-24-19 09:10PM  6-Day Deadline Alert: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS GlobeNewswire
03:09PM  Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS GlobeNewswire
01:05PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm Newsfile
Sep-23-19 10:34AM  Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE -9.51%
09:35AM  7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-20-19 03:00PM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
11:31AM  GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action ACRS GlobeNewswire
11:00AM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. GlobeNewswire
10:44AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Actions - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-19-19 07:40PM  IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -14.72%
01:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS ACCESSWIRE
11:30AM  DEADLINE: Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
Sep-18-19 07:51PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aclaris Therapeutics, Carbonite, GTT Communications, and Just Energy and Encourages Investors to Contact the Firm GlobeNewswire -9.44%
05:45PM  IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:23PM  A Look At Benzinga Pro's Most-Searched Tickers For September 18, 2019 Benzinga
10:42AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-17-19 08:49PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS GlobeNewswire +63.64%
02:45PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:29PM  A Look At Benzinga Pro's Most-Searched Tickers For September 17, 2019 Benzinga
11:15AM  Why Microcap Biotech Aclaris Is Rallying Benzinga
07:23AM  The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study Benzinga
07:00AM  Aclaris Therapeutics to Hold R&D Day GlobeNewswire
Sep-16-19 04:55PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +6.80%
04:15PM  Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2) GlobeNewswire
10:41AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:38AM  ACRS NOTICE, ROSEN, A LEADING FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action - ACRS ACCESSWIRE
09:35AM  UPCOMING DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:14AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm GlobeNewswire
Sep-14-19 07:02AM  SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-13-19 03:45PM  Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
03:15PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:00PM  SHAREHOLDER ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 GlobeNewswire
10:05AM  SHAREHOLDER ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 ACCESSWIRE
Sep-12-19 09:10PM  IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
06:20PM  GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action ACRS Business Wire
02:52PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS GlobeNewswire
Sep-11-19 09:20PM  IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:15AM  INVESTOR ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 ACCESSWIRE
Sep-10-19 07:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire +7.69%
06:20PM  SEPTEMBER DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:00PM  NATIONALLY RANKED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM ACRS GlobeNewswire
11:36AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm GlobeNewswire
10:07AM  Why Aclaris is laying off half of its staff American City Business Journals
09:15AM  ACRS DEADLINE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
Sep-09-19 12:55PM  Shareholder Alert: Robbins Arroyo LLP Reminds Shareholders That Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders Business Wire
11:25AM  UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:47AM  Chester County biopharmaceutical firm cutting 86 jobs American City Business Journals
Sep-06-19 10:55PM  ACRS DEADLINE: Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE +9.68%
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James E10% OwnerJun 27Sale2.69699,4751,882,077964,101Jul 01 05:01 PM
Flynn James E10% OwnerJun 26Sale4.501,7047,6711,072,775Jun 26 05:52 PM
Flynn James E10% OwnerJun 25Sale4.5151,484232,1361,073,127Jun 25 06:31 PM
Flynn James E10% OwnerJun 24Sale4.5263,240286,0031,083,761Jun 25 06:31 PM
Flynn James E10% OwnerJun 21Sale4.62339,5371,567,0991,096,824Jun 25 06:31 PM
Flynn James E10% OwnerMay 10Sale6.05180,5651,092,2741,166,959May 13 05:24 PM
Flynn James E10% OwnerMay 09Sale6.16434,1452,673,2481,238,828May 13 05:24 PM